The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance.


Journal

The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368

Informations de publication

Date de publication:
07 2019
Historique:
received: 09 02 2019
accepted: 09 04 2019
pubmed: 27 4 2019
medline: 10 1 2020
entrez: 27 4 2019
Statut: ppublish

Résumé

Although the presence of intraductal carcinoma of the prostate (IDC-P) influences biochemical failure in radical prostatectomy patients, no data are available regarding the impact of its integration into the classification grade group system. Thus, the aim of this study was to enhance the utility of the grade group system by integrating the presence of IDC-P. This study was a retrospective evaluation of 1019 patients with prostate cancer who underwent radical prostatectomy between 2005 and 2013 without neoadjuvant or adjuvant therapy. The data on age, prostate-specific antigen (PSA) level at diagnosis, pathological T stage (pT), presence of Gleason pattern 5 (GP5), presence of IDC-P, and surgical margin status were analyzed to predict PSA recurrence after prostatectomy. The median patient age was 67 (range, 45-80) years and the median initial PSA level was 6.8 (range, 0.4-82) ng/mL. The median follow-up period was 82 (range, 0.7-148) months. IDC-P was detected in 157 patients (15.4%). Among these patients, the increase in the positive rate of IDC-P correlated with tumor upgrading. The grade groups (GGs) were as follows: GG1 without IDC-P, 16.0% (n = 163); GG2 without IDC-P, 46.1% (n = 470); GG3 without IDC-P, 15.7% (n = 160); GG4 without IDC-P, 2.6% (n = 27); GG5 without IDC-P, 4.1% (n = 42); any GG with IDC-P, 15.4% [n = 157; GG 2 (n = 29); GG3 (n = 60); GG4 (n = 13); GG5 (n = 55)]. Any grade Group with IDC-P showed significantly worse prognosis than any other group without IDC-P (P < 0.0001). In a multivariate analysis, integration of the IDC-P into the Grade Groups, the PSA level at diagnosis, and the surgical margin status were significant prognostic predictors (P < 0.0001, < 0.0001 and < 0.0001, respectively). Integrating the presence of IDC-P into the grade group system will result in more accurate predictions of patient outcome.

Sections du résumé

BACKGROUND
Although the presence of intraductal carcinoma of the prostate (IDC-P) influences biochemical failure in radical prostatectomy patients, no data are available regarding the impact of its integration into the classification grade group system. Thus, the aim of this study was to enhance the utility of the grade group system by integrating the presence of IDC-P.
METHODS
This study was a retrospective evaluation of 1019 patients with prostate cancer who underwent radical prostatectomy between 2005 and 2013 without neoadjuvant or adjuvant therapy. The data on age, prostate-specific antigen (PSA) level at diagnosis, pathological T stage (pT), presence of Gleason pattern 5 (GP5), presence of IDC-P, and surgical margin status were analyzed to predict PSA recurrence after prostatectomy.
RESULTS
The median patient age was 67 (range, 45-80) years and the median initial PSA level was 6.8 (range, 0.4-82) ng/mL. The median follow-up period was 82 (range, 0.7-148) months. IDC-P was detected in 157 patients (15.4%). Among these patients, the increase in the positive rate of IDC-P correlated with tumor upgrading. The grade groups (GGs) were as follows: GG1 without IDC-P, 16.0% (n = 163); GG2 without IDC-P, 46.1% (n = 470); GG3 without IDC-P, 15.7% (n = 160); GG4 without IDC-P, 2.6% (n = 27); GG5 without IDC-P, 4.1% (n = 42); any GG with IDC-P, 15.4% [n = 157; GG 2 (n = 29); GG3 (n = 60); GG4 (n = 13); GG5 (n = 55)]. Any grade Group with IDC-P showed significantly worse prognosis than any other group without IDC-P (P < 0.0001). In a multivariate analysis, integration of the IDC-P into the Grade Groups, the PSA level at diagnosis, and the surgical margin status were significant prognostic predictors (P < 0.0001, < 0.0001 and < 0.0001, respectively).
CONCLUSIONS
Integrating the presence of IDC-P into the grade group system will result in more accurate predictions of patient outcome.

Identifiants

pubmed: 31025722
doi: 10.1002/pros.23818
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1065-1070

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Masashi Kato (M)

Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Akihiro Hirakawa (A)

Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Yumiko Kobayashi (Y)

Statistical Analysis Section, Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.

Akiyuki Yamamoto (A)

Department of Urology, Toyohashi Municipal Hospital, Toyohashi, Japan.

Ryo Ishida (R)

Department of Urology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan.

Tomoyasu Sano (T)

Department of Urology, Komaki City Hospital, Komaki, Japan.

Tohru Kimura (T)

Department of Urology, JCHO Chukyo Hospital, Nagoya, Japan.

Tsuyoshi Majima (T)

Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Shohei Ishida (S)

Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Yasuhito Funahashi (Y)

Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Naoto Sassa (N)

Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Takashi Fujita (T)

Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Yoshihisa Matsukawa (Y)

Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Tokunori Yamamoto (T)

Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Ryohei Hattori (R)

Department of Urology, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan.

Momokazu Gotoh (M)

Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Toyonori Tsuzuki (T)

Department of Surgical Pathology, Aichi Medical University, School of Medicine, Nagakute, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH